1. Challenging the norm: Epicutaneous immunotherapy for canine atopic dermatitis.
- Author
-
Pinto, Marta Sofia das Neves, Gil, Solange Judite Roque Coelho Alves, Ramió‐Lluch, Laura, Schmidt, Vanessa Merta, Pereira, Hugo Miguel Lino, Fernandes, Beatriz Amaral Pinto, Camões, Ana Filipa Bizarro, Morais‐Almeida, Mário, São Braz, Berta Maria Fernandes Ferreira, Marto, Joana Marques, and Lourenço, Ana Mafalda Gonçalves Xavier Félix
- Subjects
- *
ATOPIC dermatitis , *ITCHING , *DOG owners , *IMMUNOTHERAPY , *ALLERGIES , *DOG diseases - Abstract
This article discusses a clinical trial that explores the use of epicutaneous immunotherapy (EPIT) as a potential treatment for canine atopic dermatitis (cAD), a common allergic skin disease in dogs. The study aimed to assess the feasibility, effectiveness, and safety of EPIT in dogs with cAD over a six-month period. The results showed that EPIT effectively improved the dogs' clinical condition, with significant reductions in pruritus (itching), skin lesions, and improvements in quality of life. The study also found that EPIT was well-tolerated and safe, with a high adherence rate among dog owners. This pilot study suggests that EPIT could be a promising and practical treatment option for cAD in dogs, warranting further investigation. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF